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Abstracts A5
Respondent prefer to give to the young and to those who are worse off, either now
(quality of life), or in the future (prognosis). Elderly individuals, more often, prefer 
not to prioritize. It is estimated that an additional life year in a 20 year old is worth 
12.8 times the value of an additional year in an 80 year old. An additional life
year given to someone with a life expectancy of ﬁ ve years is worth 2.12 times that of 
one given to someone with a life expectancy of 10 years. An additional life year in 
someone with a utility that is 0.25 lower than someone else it is worth 2.45 times 
more. CONCLUSIONS: All results indicate that people do not think that a QALY is
a QALY and that the value of life years depends on the age of the respondent, the
prognoses of the patients and the patients’ current quality of life.
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The valuation of health beneﬁ t is arguably the most fundamental issue underpinning
all clinical and economic evaluation. However, there is disagreement about the choice
of method by which such valuation is established. Advice issued by HTA agencies
generally favours utility elicitation methods but there is growing support for simpler 
methods that evoke ordinal judgments. Decision-makers face difﬁ cult choices when 
reviewing evidence based on different valuation methods. OBJECTIVES: To examine 
the extent to which ordinal preferences captured through VAS ratings are preserved
by TTO utility elicitation methods. METHODS: The UK MVH study (n  3,395) 
provides the empirical basis for the EQ-5D values required in economic evaluations 
submitted to NICE. This study collected both VAS ratings and TTO utilities for 13
EQ-5D health states per respondent. These data have been re-analysed for the pur-
poses of this paper. RESULTS: Spearman’s Rank Correlation Coefﬁ cient (rho) for TTO 
and VAS valuations was computed on a within-subject basis for all respondents, yield-
ing a mean of 0.771. 45% of respondents had a Spearman’s rho of less than 0.80 
(equivalent to a mean absolute difference of 1.7 in ranking over all 13 states). Over 
85% of respondent’s TTO values differed in rank by more than 3/13 places when 
compared with VAS ratings. Respondent characteristics did not account for differences 
in rankings of TTO and VAS scores. CONCLUSIONS: This study shows that for 
almost half the MVH respondents, TTO utilities did not coincide with ordinal prefer-
ences as revealed by their VAS scores. These results challenge a number of basic
assumptions – about the transformation of ordinal values into cardinal utilities; the 
superiority of TTO over VAS methods and the extent to which TTO “accurately”
represents individual preferences at all. Ultimately they undermine the status of TTO 
as a legitimate measure of preferences in social decision-making.
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ORGANIZATION: Aetna Inc. is one of the nation’s leading diversiﬁ ed health
care beneﬁ ts companies, serving approximately 37.2 million people. PROBLEM OR 
ISSUE ADDRESSED: To increase the number of physicians that are NCQA Diabetes 
Physician Recognition Program (DPRP) recognized in two pilot regions. GOALS:
(1) To increase the number of high-volume Aetna contracted practitioners (PCPs) 
located in targeted geographic areas (South Florida and Southeast PA) with Diabetes
Physician Recognition Program (DPRP) recognition (2) To provide physicians
with tools to support the delivery and recognition of consistent high quality care. 
OUTCOMES ITEMS USED IN THE DECISION: Clinical efﬁ cacy/effectiveness 
IMPLEMENTATION STRATEGY: The Aetna National Quality Management Diabe-
tes Work Group met and agreed on the implementation of a three phase program to
increase the number of NCQA DPRP recognized practitioners. Aetna conducted an 
analysis of two service areas (South FL and Southeastern PA) to rank the high volume 
Aetna contracted practitioners with the most Aetna members over the age of 18 with 
a diagnosis of diabetes. The member must have been under the care of the practitioner 
in calendar year 2007. For the practitioner to qualify he must have at least 25 Aetna 
members meeting this criteria. Forty practitioners were recruited into the program 
(20 from each service area). Aetna utilized Total Therapeutic Management (TTM),
a research organization, to implement the three phase program. In phase 1, TTM
recruited the qualifying practitioners and conducted an in- ofﬁ ce chart review to
abstract data consistent with the Comprehensive Diabetes Care Healthcare Effective-
ness Data and Information Set (HEDIS) measures. TTM utilized its Diabetes Perfor-
mance and Enhancement Program (DPReP) electronic application to provide the 
practitioners with a report to see if they met the point criteria for recognition. In phase
2, TTM conducted face-to-face outreach to discuss recognition standing, patient con-
sults (ClinAdvisor), and pharmacy compliance reports. The ClinAdvisor patient con-
sults detailed clinical outcomes such as, A1C, BP, LDL goal, etc. Also during the visit
Aetna-developed tools were provided such as chart stickers, eye exam report forms,
and 3-year diabetes checklist to promote quality improvement in tracking and manag-
ing members with diabetes. TTM communicated with the practitioner during the six-
month waiting period in areas that needed improvement. In phase 3, TTM conducted 
chart reviews based on the criteria set forth by NCQA. TTM input the abstracted 
data into its electronic application to evaluate recognition status. RESULTS: In order 
to achieve diabetes recognition, practitioners must have a cumulative score of 75
points or more from ten measures related to diabetes care. Of the 40 practitioners 
that participated in the program four had the potential points necessary to meet the
recognition standing score of 75 points in the initial evaluation. After the second 
review conducted approximately six months after the ﬁ rst review, 18 practitioners 
agreed to participate in phase 3. Of the 18 practitioners participating, 17 practitioners 
met the criteria for DPRP recognition. LESSONS LEARNED: Practitioners are aware 
of the beneﬁ ts of Pay for Performance initiatives. They are also aware of the various 
recognition programs available through NCQA. Practitioners have expressed concern 
about the time or ofﬁ ce staff necessary to conduct their own chart reviews and submit
the application to become a recognized provider. If there is a process in place to 
conduct chart reviews and provide chart review-based recommendations and other
practitioner tools, there is a strong possibility that more practitioners can meet the
requirements set forth by NCQA to become a DPRP recognized provider for diabetes 
and other conditions.
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ORGANIZATION: University of Texas- MD Anderson Cancer Center (M. D. Ander-
son). PROBLEM OR ISSUE ADDRESSED: Budgets for cancer treatments are rising 
steadily with the advent of newer targeted therapies, in an era of health care cost 
containment. The issues of budgetary constraints and formulary management create
pressure on maintaining an economically viable formulary. We conducted a pre-
approval and post-approval analysis of erlotinib, an oral anti-neoplastic agent, in stage 
IIIB/IV non-small cell lung cancer (NSCLC) in the outpatient and inpatient setting at 
a tertiary cancer center as part of our Formulary Management System (FMS). GOALS:
The goal of this study is to evaluate and analyze the budget impact of erlotinib in
stage IIIB/IV NSCLC at a tertiary cancer center. The objective of the Drug Use Policy 
and Pharmacoeconomic Department is to utilize current clinical indications, resource
utilization, and cost information to perform a budget impact analysis, as part of the 
economic analysis of all new drugs considered for inclusion into the institutional 
Formulary. An economic assessment (pre-analysis) was conducted at the time of for-
mulary evaluation and addition in May 2005, and a reassessment and budget impact 
re-evaluation (post-analysis) was executed 12 months after formulary approval, from 
June 2006 to May 2007. OUTCOMES ITEMS USED IN THE DECISION: The fol-
lowing data were collected: the number of patients; the dose amount; the number of 
doses; the number of cycles; the purchase cost, the charge amount; and the reimburse-
ment amount. The budget impact analysis was executed using direct pharmaceutical 
costs adjusted to January 2008 US dollars with the aid of the Producer Price Index 
(PPI) from the U.S. Bureau of Labor Statistics. IMPLEMENTATION STRATEGY:
The pre-approval model was based on the FDA approval of erlotinib as a second line 
therapy in stage IIIB/IV NSCLC. Parameters, such as median duration of treatment 
and indications, were gathered from published clinical trials and the expected number 
of patients were estimated from expert opinion of clinicians. The pre-approval analysis 
model estimated that it would cost the institution $1,484,220 to treat 347 stage IIIB/IV
NSCLC patients for 67 days with erlotinib. This data along with a monograph was
presented to the Pharmacy and Therapeutics (P&T) committee and the drug was 
approved to be added to the institutional Formulary. RESULTS: A reassessment and
budget impact (post-approval) analysis was executed 12 months after erlotinib was 
inducted into the formulary. The analysis reviewed the non-investigational use of 
erlotinib from June 2006 to May 2007. We had 306 patients that received erlotinib 
during that time. The number of patients using erlotinib in the outpatient setting was 
267 (87%), and on the inpatient side 39 (13%) patients utilized the drug. 155 patients 
(51%) received erlotinib as second or third line therapy for treatment of stage IIIB/IV 
NSCLC, which is lower than what the pre-approval model predicted. Sixty patients 
(20%) were on erlotinib as ﬁ rst-line therapy for locally advanced, unresectable, or
metastatic pancreatic cancer, a second indication for the drug, attained after addition 
to the institutional formulary. Finally, ninety-one patients (30%) were on erlotinib for
other non-FDA approved caner indications. The overall annual budget for total erlo-
tinib usage was similar to the initial model, $1,473,085. The budget speciﬁ cally for 
NSCLC was lower at $858,904, only 58% of the predicted amount. One possible 
reason for the lower than predicted budget impact is that erlotinib is an oral agent,
which gives patients the option of obtaining the drug from an outside pharmacy closer 
to their home, rather than utilizing the institutional pharmacy. We also evaluated the 
reimbursement data for these patients, from June 2006 to May 2007, adjusting all 
values to January 2008 dollars. The reimbursement to charge ratio for NSCLC was
65%; 62% for pancreatic cancer; and 65% for the other non-FDA approved indica-
tions. Overall, the reimbursement to charge ratio for all 306 patients was 64%, which 
is favorable to our budget expectations at the institution. LESSONS LEARNED: The 
purpose of this assessment and budget impact analysis pre-and post-approval of 
the drug onto the formulary is to evaluate the budget impact of having erlotinib on
the formulary, assessing our actual utilization patterns. We were able to meet the 
reimbursement goals for the institution for all indications of erlotinib. Performing an
annual budget impact evaluation before addition of a drug to an institution’s formu-
lary, and comparing it with the annual budget impact after a sufﬁ cient time has elapsed
for penetration of product within the institution, is an essential process in determining 
